Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company’s ...
A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of the world's best selling drugs while leaving many patients struggling to ...
Hosted on MSN
Merck unveils $2B plan for AI and Delaware plant
Merck & Co. will invest up to $1 billion in a long-term Google Cloud partnership to apply artificial intelligence across drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results